via OTC PR WIRE — Kali, Inc. (dba/Kali-Extracts) (USOTC:KALY) (“KALY”) today confirmed the previously announced analyst research report featuring the company’s new cannabis biotechnology business will be released tomorrow. On November 15th, 2018, KALY acquired NCM Biotech to include a patented cannabis extraction process and associated intellectual properties consisting of years of preclinical research studies surrounding a multitude of applications of cannabis extracts derived from the patented cannabis extraction process. KALY recently published a summary of results of one of many preclinical research studies in order to present an example of the underlying value of Kali-Extracts overall cannabis biotechnology intellectual properties. KALY is currently a partner in US Cannabis Health with Puration, Inc. (USOTC:PURA) and Nouveau (USOTC:NOUV) which has signed an LOI to explore the development of cannabis therapies in partnership with Generex Biotechnology (OTCQB:GNBT). The analyst report is also expected to include detail on KALY’s recent $400,000 in new contracts and the $5 million in revenue expected from KALY’s hemp farming initiative with NOUV. KALY has recently updated all its financial reports required by OTCMarkets to satisfy the OTCMarkets “current” filing standards and anticipates the OTCMarkets site to soon reflect KALY’s “current” filing status. The analyst research report scheduled for publication tomorrow on Tuesday, January 8, 2019 is intended to augment the OTCMarkets requirements by providing shareholders with an extensive market analysis of the company’s new business plan and progress toward its new business plan objects.
To learn more about the KALY visit www.kali-extracts.com.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
<img src=”http://www.globenewswire.com/newsroom/ti?ndecode=MTUwIzc0NzQwNjU=” alt=”” width=”1″ height=”1″/>